Details

Autor(en) / Beteiligte

• Sitruk-Ware, Regine
• Bonsack, Brooke
• Brinton, Roberta
• Schumacher, Michael
• Kumar, Narender
• Lee, Jea-Young
• Castelli, Vanessa
• Corey, Sydney
• Coats, Alexandreya
• Sadanandan, Nadia
• Gonzales-Portillo, Bella
• Heyck, Matt
• Shear, Alex
• Blaise, Cozene
• Zhang, Henry
• Sheyner, Michael
• García-Sánchez, Julián
• Navarro, Lisset
• El-Etr, Martine
• De Nicola, Alejandro F.
• Borlongan, Cesar V.

Titel

Progress in progestin-based therapies for neurological disorders

Ist Teil von

• Neuroscience and biobehavioral reviews, 2021-03, Vol.122, p.38-65

Ort / Verlag

United States: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Therapeutic options for central nervous system (CNS) disorders are limited warranting the need for novel treatments.•Hormone therapy represents an innovative regenerative medicine approach for CNS disorders.•The progestin Nestorone stands as a potent therapeutic via its neurogenetic, remyelinating, and anti-inflammatory effects.•A review of preclinical and clinical evidence reveals advantages and disadvantages of progesterone, progestins, and Nestorone in CNS disorders.•Translational studies towards optimization of the drug will guide Nestorone’s entry into clinical trials. Hormone therapy, primarily progesterone and progestins, for central nervous system (CNS) disorders represents an emerging field of regenerative medicine. Following a failed clinical trial of progesterone for traumatic brain injury treatment, attention has shifted to the progestin Nestorone for its ability to potently and selectively transactivate progesterone receptors at relatively low doses, resulting in robust neurogenetic, remyelinating, and anti-inflammatory effects. That CNS disorders, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal cord injury (SCI), and stroke, develop via demyelinating, cell death, and/or inflammatory pathological pathways advances Nestorone as an auspicious candidate for these disorders. Here, we assess the scientific and clinical progress over decades of research into progesterone, progestins, and Nestorone as neuroprotective agents in MS, ALS, SCI, and stroke. We also offer recommendations for optimizing timing, dosage, and route of the drug regimen, and identifying candidate patient populations, in advancing Nestorone to the clinic.